Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469094 | 0.87 | LMNA (0.46) | MAOBCYP2D6ALOX5LTB4RLTB4R2 | |
| SCHEMBL2470933 | 0.86 | EGFR (0.48) | MAOBEGFRCYP2D6ALOX5NPC1 | |
| SCHEMBL2473768 | 0.84 | LTB4R (0.50) | MAOBEGFRCYP2D6ALOX5SMN1; SMN2 | |
| SCHEMBL4139136 | 0.79 | MAOB (0.50) | MAOBEGFRCYP2D6ALOX5NPC1 | |
| SCHEMBL2472955 | 0.76 | NPSR1 (0.38) | SMN1; SMN2 | |
| SCHEMBL3080494 | 0.71 | MAOB (0.55) | MAOBCYP2D6PTGESALOX5MAOA | |
| SCHEMBL2471737 | 0.69 | NCEH1 (0.36) | — | |
| SCHEMBL12717371 | 0.69 | FFAR1 (0.49) | MAOBCYP2D6PTGESALOX5SMN1; SMN2 | |
| SCHEMBL2475477 | 0.67 | PTGER1 (0.44) | CYP2D6ALOX5LTB4RLTB4R2 | |
| SCHEMBL9221122 | 0.67 | KDM4E (0.50) | CYP2D6NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370422-B1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2019-06-05 | — | — | EP | disclosed |
| CN-105037323-A | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN INC | 2015-11-11 | — | — | CN | disclosed |
| US-9149476-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-07-02 | — | — | US | disclosed |
| CN-102272117-B | Benzothiopyran derivatives as HIF hydroxylase inhibitors | FIBROGEN INC | 2015-06-17 | — | — | CN | disclosed |
| US-8927591-B2 | Thiochromene derivatives as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2370422-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010056767-A1 | THIOCHROMENE DERIVATIVES AS HIP HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305776-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EPOR 267/4885MAOB 1466/4885LTA4H 1090/4885 |
| US-20150182528-A1 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EPOR 267/4885MAOB 1466/4885LTA4H 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.